CNS delivery of therapeutic agents
AssigneeTakeda Pharmaceutical Company Limited
InventorsPericles Calias, Jing Pan, Jan Powell, Lawrence Charnas, Thomas McCauley, Teresa Leah Wright, Richard Pfeifer, Zahra Shahrokh
Life of this patent
Estimating the term…
Abstract
The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.
Claims5
A formulation comprising a lysosomal enzyme at a concentration of at least 5 mg/ml and a surfactant, wherein the formulation comprises no greater than 5 mM phosphate and has a pH of 5.5-7.0, wherein the surfactant is polysorbate 20 or polysorbate 80, and wherein the formulation is suitable for CNS delivery.
Dependencies are inferred from the claim text.